[
  {
    "ts": null,
    "headline": "The Bull Case For Regeneron (REGN) Could Change Following European Approval of Dupixent for CSU Patients",
    "summary": "Regeneron Pharmaceuticals and Sanofi recently announced that the European Commission approved Dupixent as a first-line treatment for moderate-to-severe chronic spontaneous urticaria (CSU) in patients aged 12 and older who do not respond to antihistamines and are naive to anti-IgE therapy, based on positive Phase 3 clinical trial results. This marks the first innovation for CSU patients in Europe in over a decade and potentially opens access for approximately 270,000 eligible...",
    "url": "https://finnhub.io/api/news?id=6ecfde36c53fe0cbfbd90da2d64312e9caf2cfc0317b45996494399e0fbfac6c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764317361,
      "headline": "The Bull Case For Regeneron (REGN) Could Change Following European Approval of Dupixent for CSU Patients",
      "id": 137628398,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals and Sanofi recently announced that the European Commission approved Dupixent as a first-line treatment for moderate-to-severe chronic spontaneous urticaria (CSU) in patients aged 12 and older who do not respond to antihistamines and are naive to anti-IgE therapy, based on positive Phase 3 clinical trial results. This marks the first innovation for CSU patients in Europe in over a decade and potentially opens access for approximately 270,000 eligible...",
      "url": "https://finnhub.io/api/news?id=6ecfde36c53fe0cbfbd90da2d64312e9caf2cfc0317b45996494399e0fbfac6c"
    }
  },
  {
    "ts": null,
    "headline": "Deutsche Bank Maintains a Buy Rating on Sanofi (SNY)",
    "summary": "Sanofi (NASDAQ:SNY) is one of the best low volatility large cap stocks to invest in. Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Sanofi (NASDAQ:SNY) on November 25, setting a €110 price target. The same day, Sanofi (NASDAQ:SNY) announced the approval of Dupixent (dupilumab) by the European Commission for the treatment of “moderate-to-severe chronic […]",
    "url": "https://finnhub.io/api/news?id=b7cf50e384d8751b70bf585e13fc7be801935c3d5003f4529db3f982f20de44c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764314390,
      "headline": "Deutsche Bank Maintains a Buy Rating on Sanofi (SNY)",
      "id": 137628399,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Sanofi (NASDAQ:SNY) is one of the best low volatility large cap stocks to invest in. Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Sanofi (NASDAQ:SNY) on November 25, setting a €110 price target. The same day, Sanofi (NASDAQ:SNY) announced the approval of Dupixent (dupilumab) by the European Commission for the treatment of “moderate-to-severe chronic […]",
      "url": "https://finnhub.io/api/news?id=b7cf50e384d8751b70bf585e13fc7be801935c3d5003f4529db3f982f20de44c"
    }
  }
]